Treatment with deferiprone for iron overload alleviates bone marrow failure in a fanconi anemia patient

Hemoglobin

Volumn 33, Issue 5, 2009, Pages 346-351

  Chang, Yu Hsiang ^a,b,c   Shaw, Chen Fu ^a   Wu, Kang Hsi ^d   Hsieh, Kai Hsien ^b   Su, Yi Ning ^e   Lu, Pei Jung ^f  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Deferiprone (L1); Fanconi anemia

Indexed keywords

DEFERIPRONE; FERRITIN; HEMOGLOBIN;

BONE MARROW DEPRESSION; CASE REPORT; CHILD; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FANCONI ANEMIA; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; LEUKOCYTE COUNT; MALE; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

BONE MARROW; CHILD; FANCONI ANEMIA; FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PLATELET COUNT; PYRIDONES;

EID: 70350643852     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903212563     Document Type: Conference Paper

References (18)

1. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol. 2006;43(3):147-156.
2. Butturini A, Gale RP, Verlander PC, et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994;84(5):1650-1655.
3. Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol. 1993;21(6):731-733.
4. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249-1256.
5. Collins N, Kupfer GM. Molecular pathogenesis of Fanconi anemia. Int J Hematol. 2005;82(3): 176-183.
6. Levran O, Diotti R, Pujara K, et al. Spectrum of sequence variations in the FANCA gene: an International Fanconi Anemia Registry (IFAR) study. Hum Mutat. 2005;25(2):142-149.
7. Tamary H, Dgany O, Toledano H, et al. Molecular characterization of three novel Fanconi anemia mutations in Israeli Arabs. Eur J Haematol. 2004;72(5):330-335.
8. Yagasaki H, Hamanoue S, Oda T, et al. Identification and characterization of novel mutations of the major Fanconi anemia gene FANCA in the Japanese population. Hum Mutat. 2004;24(6): 481-490.
9. Ameziane N, Errami A, Leveille F, et al. Genetic subtyping of Fanconi anemia by comprehensive mutation screening. Hum Mutat. 2008;29(1):159-166.
10. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations. Br J Haematol. 1990;76(2):301-304.
11. Pagano G, Degan P, d'Ischia M, et al. Oxidative stress as a multiple effector in Fanconi anaemia clinical phenotype. Eur J Haematol. 2005;75(2):93-100. (Pubitemid 41008278)
12. Pearl-Yafe M, Halperin D, Scheuerman O, Fabian I. The p38 pathway partially mediates caspase-3 activation induced by reactive oxygen species in Fanconi anemia C cells. Biochem Pharmacol. 2004;67(3):539-546.
13. Liu J, Finkel T. Stem cell aging: what bleach can teach. Nat Med. 2006;12(4):383-384.
14. Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12(4):446-451.
15. Ito K, Hirao A, Arai F, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431(7011):997-1002.
16. Zhang X, Sejas DP, Qiu Y, et al. Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. J Cell Sci. 2007;120(Pt. 9):1572-1583.
17. Korkina L, De Luca C, Deeva I, et al. L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients. Transfus Sci. 2000;23(3):253-254.
18. Afanas'ev IB, Afanas'ev II, Deeva IB, Korkina LG. Free radical formation and oxyhemoglobin oxidation in b-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1. Transfus Sci. 2000;23(3):237-238.